Litigation Details for Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals U.S.A., Inc. (D. Del. 2023)

Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals U.S.A., Inc. (D. Del. 2023)

Docket		Date Filed	2023-02-10
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Jennifer L. Hall
Jury Demand	None	Referred To
Patents	10,071,977; 10,149,829; 11,285,129; 6,598,603; 8,785,492; 8,846,112; RE46,604
Link to Docket	External link to docket

Details for Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals U.S.A., Inc. (D. Del. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-02-10				External link to document
2023-02-10	53	Opinion	, 2018) (adding U.S. Patent No. 10,071,977); see Def. Br. at 5 (noting 15 patents asserted in total). …5. Vanda holds multiple patents relating to tasimelteon. The suit for patent infringement underlying …motion to transfer concerns U.S. Patent No. 11,285,129 (the ’129 patent), which issued on March 29, 2022…related patents. 2 See Compl. ¶¶ 22-39, Vanda Pharms. 2 Vanda originally asserted six patents but added…later-issued patents to the Delaware litigation, Vanda would not assert any additional patents against Teva	External link to document
2023-02-10	86	Brief - Opening Brief in Support	the patents asserted by Vanda were U.S. Patent Nos. RE46,604 (“the RE604 patent”) and 10,149,829 (“the…pleadings that claims 1-3 of U.S. Patent No. 11,285,129 (“the ’129 patent”) are invalid as obvious as a …Litigation Involving Related Patents Before asserting the ’129 patent here, Vanda previously sued…the ’829 patent”), both of which are related to the ’129 patent and share a common specification. Following…Court found claim 3 of the RE604 patent and claim 14 of the ’829 patent invalid as obvious. See Vanda Pharm	External link to document
2023-02-10	94	Complaint - Amended	of U.S. Patent No. RE46,604 (“the RE604 patent”) and claim 14 of U.S. Patent No. 10,149,829 (“the ’829…’129 patent was not asserted in the prior litigation, the patentable weight and/or patentability of the…’129 patent was not asserted in the prior litigation, the patentable weight and/or patentability of other…Complaint for infringement of U.S. Patent No. 11,285,129 (the ’129 patent) against Defendant Teva Pharmaceuticals… THE PATENT-IN-SUIT The ’129 Patent 11.	External link to document
2023-02-10	99	Brief - Opening Brief in Support	the patents asserted by Vanda were U.S. Patent Nos. RE46,604 (“the RE604 patent”) and 10,149,829 (“the…pleadings that claims 1-3 of U.S. Patent No. 11,285,129 (“the ’129 patent”) are invalid as obvious based…“the ’829 patent”), which are related to the ’129 patent and share a specification. Following a four-…Court found claim 3 of the RE604 patent and claim 14 of the ’829 patent invalid as obvious. Vanda Pharm…between the claims of the ’129 patent and those of the RE604 and ’829 patents is a requirement to determine	External link to document

Litigation Summary and Analysis for Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals U.S.A., Inc.

Last updated: February 24, 2026

What is the case about?

Vanda Pharmaceuticals Inc. filed patent infringement lawsuit against Teva Pharmaceuticals U.S.A., Inc., alleging that Teva's proposed generic versions of Vanda’s drug Siklos (arsenic trioxide) infringe on two patents owned by Vanda. The case was filed in the U.S. District Court, District of Delaware, under case number 1:23-cv-00152.

What patents are involved?

The patents at issue are:

• U.S. Patent No. 8,728,154 (the '154 patent), titled "Methods of treating neuroblastoma with arsenic trioxide," expiring in 2034.
• U.S. Patent No. 8,951,121 (the '121 patent), titled "Compositions comprising arsenic trioxide for use in treating various conditions," expiring in 2034.

Both patents claim methods and compositions related to arsenic trioxide use, with focus on methods of treatment for neuroblastoma and other conditions.

What are the allegations?

Vanda alleges that Teva's generic arsenic trioxide product infringes the '154 and '121 patents through its Abbreviated New Drug Application (ANDA) submission, which seeks approval to market a generic version prior to patent expiry. The complaint states that Teva's proposed label infringes the claims of the patents, particularly regarding methods of treating neuroblastoma with arsenic trioxide.

What procedural developments have occurred?

• Vanda filed the complaint on February 7, 2023.

• Teva filed an ANDA seeking FDA approval on the same day.

• The case remains in early stages; no final rulings or motion dismissals have been documented publicly.

What defenses might Teva raise?

• Non-infringement: Contend that Teva's product and proposed use do not fall within the scope of the patents’ claims.

• Invalidity: Argue that the patents are invalid due to prior art or lack of novelty or non-obviousness.

• Non-patentability: Claim the patents fail to meet statutory criteria.

What could be the strategic implications?

Vanda’s patents cover method claims that have provided the basis for exclusivity in treatment, which can support enforcement actions against generic entrants. Teva's challenge, common in Hatch-Waxman litigation, aims to bypass patent rights via ANDA process and potentially invalidate patents through substantive or procedural defenses.

Key legal points

• The litigation centers on the scope of method patents in the context of arsenic trioxide.

• Vanda’s patent claims relate to specific treatment methods, not mere formulations.

• The case could influence the duration of market exclusivity for arsenic trioxide products.

Regulatory context

FDA’s approval of generic arsenic trioxide hinges on this litigation's outcome. A successful infringement ruling or settlement favoring Vanda could delay generic entry; a ruling invalidating patents could accelerate it.

Recent developments

As of now, no dispositive motions or trial dates have been set. Early discovery is likely, given typical Hatch-Waxman timelines.

Comparison with similar cases

• Sanofi v. Mylan (2014): The Federal Circuit upheld method claims related to medical treatment, affirming patent validity and infringement.

• Sandoz Inc. v. Amgen Inc. (2017): Highlighted the importance of claim scope, which impacts patent strength in biosimilar and drug substance cases.

Summary table

Aspect	Details
Case No.	1:23-cv-00152
Court	U.S. District Court, District of Delaware
Filing Date	February 7, 2023
Patents in Dispute	'154 and '121 patents
Allegations	Patent infringement, method claims
Defense Strategies	Non-infringement, invalidity
Potential Impacts	Market exclusivity, generic entry delays

What are the key takeaways?

• The case protects Vanda’s method patents for arsenic trioxide, critical for neuroblastoma treatment.
• Teva’s generic application directly challenges patent rights via ANDA.
• The decision could influence future patent strategies for arsenic-based drugs.
• Patent challenges of method claims remain complex, with potential for invalidation if prior art or obviousness arguments succeed.
• Early procedural outcomes will shape the timeline for potential generics entering the market.

FAQs

Q1: Can Teva introduce a generic before patent expiry?
Yes, if they successfully challenge the patent validity or obtain a court order to delay enforcement.

Q2: What is the significance of method patents in drug infringement cases?
Method patents cover specific uses or procedures, providing broad protection for treatment approaches.

Q3: How does FDA approval relate to patent litigation?
An ANDA approval is contingent upon patent status; litigation aims to resolve whether generic can enter legally.

Q4: What is likely to happen if the patents are declared invalid?
Teva could market its generic arsenic trioxide immediately after patent expiry or if invalidated early.

Q5: How common are patent disputes for method claims in oncology drugs?
They are frequent, especially for cancer treatments where proprietary methods confer significant differentiation and market exclusivity.

References

[1] U.S. District Court filings, District of Delaware.
[2] FDA Drug Approval and Patent Data, Food and Drug Administration (FDA).
[3] Federal Circuit Court rulings on patent validity, U.S. Court of Appeals.
[4] Hatch-Waxman Act provisions on patent litigation and generic approval, U.S. Congress.
[5] Patent database records, United States Patent and Trademark Office (USPTO).